Flud Christopher R, Duarte-Rojo Andres
College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
J Clin Exp Hepatol. 2019 Jan-Feb;9(1):112-116. doi: 10.1016/j.jceh.2018.04.009. Epub 2018 May 4.
Minimal or Covert Hepatic Encephalopathy (MHE/CHE), the preclinical phase of Hepatic Encephalopathy (HE), is strongly associated with poorer Quality of Life (QOL), Overt HE (OHE), and death. Several diagnostic tests have been developed that have prognostic value in predicting clinical outcomes such as OHE, cirrhosis progression, and death. However, dispute among clinicians and HE researchers have kept its application largely underutilized. Current issues contributing to the confusion include: lack of a formal definition for CHE, uncertainty of which diagnostic tools to use, and whether one or two abnormal tests are required for a diagnosis. Due to this misunderstanding, the aims of this review were to consolidate large-scale ( ≥ 100) validation studies in order to discuss these obstacles and make recommendations for improving our approach to MHE/CHE. The studies included in this review are a great resource for initiating a unified effort for advancement in HE, and as such, it is our hope that this will drive progress toward common goals that will permanently improve the lives of patients with cirrhosis.
轻微型或隐匿型肝性脑病(MHE/CHE)是肝性脑病(HE)的临床前期,与较差的生活质量(QOL)、显性肝性脑病(OHE)及死亡密切相关。目前已开发出多种诊断测试,这些测试在预测诸如OHE、肝硬化进展及死亡等临床结局方面具有预后价值。然而,临床医生和HE研究人员之间的争议使得其应用在很大程度上未得到充分利用。导致这种混乱的当前问题包括:缺乏CHE的正式定义、使用何种诊断工具存在不确定性,以及诊断需要一项还是两项异常测试。由于这种误解,本综述的目的是汇总大规模(≥100)验证研究,以便讨论这些障碍,并就改进我们对MHE/CHE的处理方法提出建议。本综述纳入的研究是推动HE统一进展的重要资源,因此,我们希望这将推动朝着共同目标取得进展,从而永久性改善肝硬化患者的生活。